Complement Regulation to Undo Systemic Harm in Preeclampsia

Summary

This study focuses on pregnant women (between 23 and 30 weeks) who have been diagnosed with preeclampsia. The purpose of the study is to determine whether an investigational drug called eculizumab is an effective treatment for preeclampsia. Specifically, researchers will evaluate whether treatment with eculizumab prolongs pregnancy in women with preterm preeclampsia, compared to a group of women (historical control group) with preterm preeclampsia who did not receive eculizumab. 

Eculizumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain blood disorders and has been used in pregnant women, but it is not approved by the FDA for the treatment of preeclampsia.


Inclusion Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures & availability for study duration
  • Biologically female, aged ≥13, body weight ≥40kg
Show more

Study Location(s)

Beverly

More about this Clinical Trial

Full Title

Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study

Details
Disease Type/Condition

Other

Principal Investigator

Burwick, Richard

Age Group

Adult

Phase

II

IRB Number

STUDY00000039

ClinicalTrials.gov ID

NCT04725812

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Other

Principal Investigator

Burwick, Richard

Age Group

Adult

Phase

II

IRB Number

IIT-BURWICK2019

ClinicalTrials.gov ID

NCT04725812

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?